- Citigroup Talks, But Nothing 'Walks' To Stabilize
- Soros: More Money Needed For U.S. Bailout
- HP Earnings: How Much Will "Hurt" From Economy?
- Obama Warns On Economy: Works On Stimulus Plan
- Citigroup's Ills May Signal Market Isn't Near Bottom
- US Inflation Bonds Hit by Deflation, May Recover
- Pros Say: Market Will Drop 5-10% — Ford Will Boom
- Bonds Drop on Profit-Taking, Geithner Move
- Jack Welch on Detroit: Let Them Go Bankrupt
- Out with Cox, in with Uptick Rule
- Pops & Drops: Hewlett-Packard, JP Morgan & Air Wagoner
- Mad Money Green Week: Owens Corning
- Fast & Furious: It's All About Soup
- Web Extra: The Trade on Walmart and RIMM
- Chartology: Grossly Oversold and Favoring the Upside
- The "Armageddon" Gameplan
- What's Next for Citigroup?
- What to Expect From a Geithner-led Treasury
Two reports and an editorial in "The New England Journal of Medicine" are raising questions again about the potentially higher risk of death from cancer associated with a popular cholesterol-fighting drug.
An analysis of three large studies of Vytorin from Merck [MRK
Loading...
()
] and Schering-Plough [SGP
Loading...
()
] counts 134 cancer-related deaths among patients taking the drug versus 92 deaths in patients getting a placebo or the cholesterol drug Zocor.
Some experts and the companies say the higher number of fatalities is due to chance and an anomaly.
But researchers in NEJM say the difference is cause for concern and warrants further study.
In addition, a NEJM editorial says, "It is appropriate to raise a note of caution," and that doctors and patients "are left, for now, with uncertainty about the efficacy and safety of the drug."
Vytorin is a mixture of Merck's Zocor and Schering-Plough's Zetia. Vytorin and Zetia prescriptions have fallen, as well as the stock prices of Merck and Schering-Plough, since a piece of the cancer data and another study about the drugs' efficacy were released over the past several months.
Last year, the companies sold around $5 billion worth of the pills.





